Effective treatment of hypereosinophilic syndrome with imatinib mesylate

Hematology Journal

Volumn 4, Issue 6, 2003, Pages 410-412

  Salem, Ziad ^a   Zalloua, Pierre A ^b   Chehal, Aref ^a   Bitar, Nizar ^c   Abboud, Miguel ^a,d   Kadri, Adel ^e   Chami, Beatrice ^f   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c Sahel Hospital   (Lebanon)

^d Childrens Cancer Center of Lebanon   (Lebanon)

^e Tell Chiha Hospital   (Lebanon)

^f Liban   (Lebanon)

Author keywords

Eosinophilia; Hypereosinophilic syndrome; Imatinib mesylate; Leukemia

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CORTICOSTEROID; CYTARABINE; HYBRID PROTEIN; HYDROXYUREA; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD DISEASE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; KARYOTYPE; LABORATORY TEST; MALE; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; TRISOMY 8;

ADULT; BASE SEQUENCE; CHILD; CHROMOSOMES, HUMAN, PAIR 8; DNA PRIMERS; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; HYPEREOSINOPHILIC SYNDROME; KARYOTYPING; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRISOMY;

EID: 0346505232     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200294     Document Type: Article

References (5)

1. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-487.
2. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.
3. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001; 3: 9.
4. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002; 359: 1577-1578.
5. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Res 2002; 26: 881-884.